Pharvaris text logo
  • our science
  • our pipeline
  • disease focus: HAE
  • HAE community
  • clinical trials
  • about us
    • about us
    • join us
    • contact
  • investors

Tailored drug development for patients living with HAE

by Pharvaris | Dec 9, 2022

Latest News

  • Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting 1st February 2021
  • Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema 27th January 2021
  • Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director 5th January 2021
  • Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE 18th November 2020
  • Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE 13th November 2020

Categories

  • Board
  • In Memoriam
  • Management & Founders
  • News
  • Publications
  • Scientific Advisors

Privacy    Cookie notice    Terms of Use

Pharvaris 2023 © All rights reserved

contact us